1. Home
  2. MCB vs AKBA Comparison

MCB vs AKBA Comparison

Compare MCB & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metropolitan Bank Holding Corp.

MCB

Metropolitan Bank Holding Corp.

HOLD

Current Price

$94.25

Market Cap

906.2M

Sector

Finance

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.18

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCB
AKBA
Founded
1999
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
906.2M
729.1M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
MCB
AKBA
Price
$94.25
$1.18
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$97.50
$5.92
AVG Volume (30 Days)
110.5K
3.4M
Earning Date
04-21-2026
04-12-2026
Dividend Yield
0.85%
N/A
EPS Growth
11.64
N/A
EPS
6.62
0.03
Revenue
$11,053,000.00
N/A
Revenue This Year
$33.38
$47.43
Revenue Next Year
$9.32
$17.65
P/E Ratio
$24.19
$39.33
Revenue Growth
N/A
N/A
52 Week Low
$47.08
$1.14
52 Week High
$97.84
$4.08

Technical Indicators

Market Signals
Indicator
MCB
AKBA
Relative Strength Index (RSI) 60.60 31.93
Support Level $92.13 $1.15
Resistance Level $96.33 $1.60
Average True Range (ATR) 3.10 0.09
MACD -0.57 -0.02
Stochastic Oscillator 58.14 0.00

Price Performance

Historical Comparison
MCB
AKBA

About MCB Metropolitan Bank Holding Corp.

Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: